Related Experiment Video
Updated: Oct 12, 2025
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
Chemerin-Derived Peptide Val66-Pro85 Is Effective in Limiting Methicillin-Resistant S. aureus Skin Infection
Aneta Zegar1, Urszula Godlewska1, Dorota Kozłowska-Chmielewska1
1Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland.
Abstract:
Chemerin-derived peptide Val66-Pro85 (p4) restricts the growth of a variety of skin-associated bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). To better understand the antimicrobial potential of chemerin peptide, we compared p4 activity against MRSA in vitro to cathelicidin LL-37, one of the key endogenous peptides implicated in controlling the growth of S. aureus. The efficacy of p4 was also validated in relevant experimental models of skin pathology, such as topical skin infection with community-acquired MRSA, and in the context of skin inflammatory diseases commonly associated with colonization with S. aureus, such as atopic dermatitis (AD). We showed that p4 collaborates additively with LL-37 in inhibiting the growth of S. aureus, including MRSA, and that p4 was effective in vivo in reducing MRSA burden. p4 was also effective in reducing levels of skin-infiltrating leukocytes in S. aureus-infected AD-like skin. Taken together, our data suggest that p4 is effective in limiting S. aureus and, in particular, MRSA skin infection.
Insights
Chemerin peptide p4 effectively inhibits methicillin-resistant Staphylococcus aureus (MRSA) skin infections. It works with cathelicidin LL-37 and reduces bacterial burden and inflammation in skin models.
Area of Science:
- Microbiology
- Dermatology
- Immunology
Background:
- Chemerin-derived peptide Val66-Pro85 (p4) shows antimicrobial activity against skin bacteria.
- Methicillin-resistant Staphylococcus aureus (MRSA) is a significant pathogen in skin infections.
- Cathelicidin LL-37 is an endogenous peptide crucial for controlling S. aureus growth.
Purpose of the Study:
- To compare the antimicrobial activity of p4 against MRSA with cathelicidin LL-37.
- To evaluate the efficacy of p4 in experimental models of MRSA skin infection and atopic dermatitis (AD).
Main Methods:
- In vitro antimicrobial assays comparing p4 and LL-37 against MRSA.
- In vivo studies using a mouse model of topical MRSA skin infection.
- Assessment of p4 in a mouse model of S. aureus-infected atopic dermatitis-like skin.
Main Results:
- p4 demonstrated additive antimicrobial effects when combined with LL-37 against S. aureus and MRSA.
- p4 significantly reduced MRSA bacterial burden in vivo.
- p4 decreased skin-infiltrating leukocytes in S. aureus-infected AD-like skin.
Conclusions:
- p4 is a promising therapeutic agent for limiting S. aureus and MRSA skin infections.
- p4 exhibits efficacy in both direct antimicrobial action and modulating the inflammatory response in skin.
More Related Videos
Related Concept Videos
01:28Antimicrobial Effectiveness
01:18Surface Membrane Barriers
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...